

1 WO

2
3
4
5
6 **IN THE UNITED STATES DISTRICT COURT**
7
8 **FOR THE DISTRICT OF ARIZONA**

9 Ahmad Alsadi and Youssra Lahlou,
10 husband and wife,

11 Plaintiffs,

12 v.

13 Intel Corporation, a Delaware
14 corporation; et.al.,

15 Defendants.

NO: CV16-03738-PHX-DGC

ORDER

16 Defendant Intel filed a trial brief asking that the Court preclude Plaintiffs from
17 presenting independent medical evaluations (IMEs) from Drs. Schwartzberg and Leff, and
18 deposition testimony from Dr. Schwartzberg. Doc. 298. The parties have fully briefed the
19 issue (Docs. 308, 319) and no party requests oral argument.

20 Plaintiffs have the burden of demonstrating the admissibility of the IMEs and the
21 deposition testimony. The Court will address each of the parties' arguments.

22 **A. The Court's Prior Ruling.**

23 The Court previously excluded the expert opinions of Drs. Schwartzberg and Leff
24 because they were not timely disclosed by Plaintiffs as experts in this case. Doc. 279 at 35-
25 38.¹ The Court's order concerned opinions rendered in the doctors' IMEs. *See id.* at 35
26

27 ¹ Upon reviewing its previous ruling at Doc. 279, the Court noted a typo at page 36,
28

1 (“Plaintiffs disclosed [the doctors] as persons who may have knowledge regarding their
2 findings and independent medical examinations of Alsadi in his worker’s compensation
3 matter.”). Because the Court has already excluded these opinions, Plaintiffs may not present
4 them at trial by introducing the IMEs in evidence. The excluded opinions are found in the
5 “Discussion” and “Answers to specific questions” portions of Dr. Schwartzberg’s June 23,
6 2016 IME (Doc. 149-3 at 4-6), the “Conclusions” and “Answers to specific questions”
7 portions of his November 9, 2016 IME (Doc. 149-4 at 4-5), and the “Conclusions,”
8 “Discussion,” and “Answers to specific questions” portions of Dr. Leff’s January 18, 2017
9 IME (Doc. 161-12 at 4-6).² Because the IMEs contain more than the doctors’ opinions,
10 including Mr. Alsadi’s description of the cause and course of his symptoms, the Court will
11 address the various hearsay objections briefed by the parties.³

12 **B. Hearsay Objections.**

13 **1. Rules 703 and 705.**

14 Plaintiffs argue that the IMEs are admissible under Rule 703 because they were relied
15 on by several defense experts who will testify at trial. But Rule 703 does not authorize the
16 general admission of otherwise inadmissible evidence simply because it was relied on by a
17 testifying expert. The rule permits the use of such evidence for the purpose of evaluating the
18 expert’s opinion. *See* Fed. R. Evid. 703 Advisory Committee Note (2000); 4 Weinstein’s
19

20
21 line 13. The phrase “does justify” should be “does not justify.” Although this meaning is
22 clear from the two case quotations that follow the phrase and the Court’s exclusion of the
23 Schwartzberg and Leff opinions (Doc. 279 at 38), the Court provides this clarification to
24 remove any doubt.

25 ² In arguing that the opinion portions of the IMEs may be admitted notwithstanding
26 the Court’s previous ruling, Plaintiffs cite cases applying Rule 803(6) and holding that
27 admissible business records may include opinions. Doc. 308 at 2-3 & n.3. But Rule 803(6)
28 concerns hearsay objections. It does not address, and certainly does not cure, Plaintiffs’
failure to disclose Drs. Schwartzberg and Leff as expert witnesses under Federal Rule of
Civil Procedure 26(a)(2) – the basis for the Court’s previous exclusion order. *See* Doc. 279
at 35-38.

³ Defendant argues that the IMEs are not admissible under Rule 801(d)(2). But other
than asserting that statements offered by an opposing party are presumed reliable (Doc. 308
at 6), Plaintiffs do not mention Rule 801(d)(2). *See* Doc. 308 at 6.

1 Federal Evidence § 705.03 (2020) (“If the court allows disclosure of inadmissible facts on
2 direct examination, the court, on request, should give the jury a limiting instruction informing
3 it that the underlying information must not be used for any substantive purpose, but only in
4 evaluating the strength of the opinion.”). Furthermore, ““Rule 703 is not, itself, an exception
5 to or exclusion from the hearsay rule or any other evidence rule that makes the underlying
6 information inadmissible.”” *In Re Bard IVC Filters Products Liability Lit.*, No. CV-16-
7 00474-PHX-DGC, 2018 WL 1109554, at *9 (D. Ariz. March 1, 2018) (quoting 4 Weinstein’s
8 Federal Evidence §703.05). Thus, Plaintiffs cannot rely on Rule 703 to admit the IMEs for
9 general substantive use at trial. If an expert has relied on an IME in forming his or her
10 opinions, Plaintiffs may cross-examine the expert about the IME to the extent the IME is
11 relevant in evaluating the opinions.⁴

12 Plaintiffs also argue that the IMEs are admissible under the last sentence of Rule 705.
13 But that sentence – which states that an expert may be required on cross-examination to
14 disclose information underlying the expert’s opinion – does not expand the use of the
15 underlying information beyond that permitted in Rule 703; the disclosure is still allowed
16 only for the purpose of evaluating the expert’s opinion. Nothing in Rule 705 suggests that
17 otherwise inadmissible underlying information may be admitted for general substantive
18 purposes.⁵ Thus, as noted above, if experts have relied on the IMEs, Plaintiffs may question
19

21 ⁴ If the testifying expert relied on the expert opinion portions of the IME – the portions
22 excluded from evidence in the Court’s previous ruling, as discussed above – those portions
23 may still be used to cross-examine the testifying expert, but only for purposes of evaluating
24 the testifying expert’s opinion. The opinion portions of the IME may not be used as
substantive evidence of the IME doctor’s opinion for purposes of determining the cause or
25 extent of Mr. Alsadi’s injuries. This distinction comports not only with Rule 703, but also
26 with the Court’s ruling on the opinions of Drs. Schwartzberg and Leff. Doc. 279 at 35-38.

27 ⁵ Rule 705 concerns trial efficiency, and eliminates the common law requirement that
28 all facts and data underlying an expert’s opinion must be disclosed to the trier of fact before
any opinion is stated. *See* 5 Weinstein’s Federal Evidence § 705 App. 100 (2020). The last
sentence was added to make clear that the rule did not prohibit the opposing party from
eliciting the underlying facts and data during cross-examination in order to challenge the
credibility of the opinion. 4 Weinstein’s Federal Evidence § 705.05 (2020). The Advisory

1 them about the IMEs to the extent relevant to evaluating the expert’s opinions. Plaintiffs
2 may not use Rule 705 to admit the IMEs for general substantive purposes.

3 In sum, Rules 703 and 705 provide no basis for overcoming Defendant’s hearsay
4 objections to the general admission of the IMEs. But Plaintiffs may inquire about the IMEs
5 on cross-examination of testifying experts who have relied on the IMEs, to the extent
6 relevant to evaluating the experts’ opinions.

7 **2. Rule 803(4).**

8 Plaintiffs assert that the IMEs are admissible under Rule 803(4) because they contain
9 statements made by Mr. Alsadi for purposes of a medical diagnosis or treatment. For
10 Rule 803(4) to apply, however, “[t]he declarant herself must understand that she is providing
11 information for purposes of diagnosis or treatment because that understanding is what
12 provides assurance that the statements are particularly likely to be truthful.” *United States*
13 *v. Kootswatewa*, 893 F.3d 1127, 1133 (9th Cir. 2018). In this case, Drs. Schwartzberg and
14 Leff – who performed the IMEs at the request of the insurer of Mr. Alsadi’s employer in
15 connection with his worker’s compensation claim – specifically advised Mr. Alsadi that the
16 IMEs were not being conducted as part of a physician-patient relationship. *See Docs. 149-3*
17 *at 2; 149-4 at 2; 161-12 at 2.* Mr. Alsadi therefore would not have understood that he was
18 providing information for purposes of diagnosis or treatment.
19

20 Plaintiffs argue that Drs. Schwartzberg and Leff provided medical advice or
21 prescribed medication for Mr. Alsadi. But “it is the declarant’s understanding of the
22 purposes for which the statements were made that matters under Rule 803(4).”
23 *Kootswatewa*, 893 F.3d at 1133. The doctors made clear at the outset of the IMEs that they
24 would not be acting as Mr. Alsadi’s doctors. *See Docs. 149-3 at 2; 149-4 at 2; 161-12 at 2.*
25

26
27 Committee Notes to Rule 705 suggest that the last sentence affords the cross-examiner an
28 opportunity to “bring out facts and data . . . unfavorable to the opinion.” Fed. R. Evid. 705,
Advisory Committee Note (1972).

1 The Court accordingly concludes that the IMEs and Mr. Alsadi's statements quoted in the
2 IMEs are not admissible under Rule 803(4).⁶

3 **3. Rule 803(6).**

4 Defendant argues that the IMEs are not admissible as business records because they
5 were not made in the regular course of business by Drs. Schwartzberg and Leff. The Court
6 cannot agree. Both doctors are in the business of performing medical evaluations, and the
7 Advisory Committee Notes to Rule 803(6) specifically state that "[a] physician's evaluation
8 report of a personal injury litigant would appear to be in the routine of his business." Fed.
9 R. Evid. 803(6), Advisory Committee Note (1972).

10 Defendant also argues that the report is inadmissible because it was made in
11 connection with litigation and therefore is untrustworthy. *See* Fed. R. Evid. 803(6)(E). The
12 Court is not persuaded, however, that the circumstances under which the IMEs were created
13 show such a lack of trustworthiness. Although the IMEs contain recitations by Mr. Alsadi
14 of his history and condition made in the context of his worker's compensation claim, the
15 IMEs were performed and documented by doctors whose reliability Defendant does not
16 question, and reported facts on which the doctors relied. Further, the IMEs show that Mr.
17 Alsadi stated at several points that his condition had improved, which suggests he was not
18 merely advocating for his disability. *See* Docs. 149-3 at 3, 149-4 at 2.⁷

21
22 ⁶ Plaintiffs cite language from *Kootswatewa* stating that "[a]bsent evidence indicating
23 otherwise, the district court could reasonably infer . . . that [Mr. Alsadi] understood [he] was
24 providing information for purposes of diagnosis or treatment." 893 F.3d at 133. But in this
25 case, there is evidence "indicating otherwise." *See id.* Both doctors told Mr. Alsadi there
26 would be no physician-patient relationship. Plaintiffs also argue that Mr. Alsadi's statements
27 to the doctors are not being offered for the truth of the matter asserted and therefore are not
28 hearsay. Doc. 308 at 9. The Court does not agree. His statements to the doctors concerned
his physical condition, and Plaintiffs argue strenuously that the IMEs accurately reflect his
condition at the time – that Mr. Alsadi's statements about his condition are true.

⁷ Nor is the Court persuaded by Defendant's argument that the IMEs were not made
"at or near the time" as required by Rule 803(6)(A). The IMEs were made at or near the
time of Mr. Alsadi's examination by the doctors.

1 The Court cannot, however, conclude at this point that the IMEs are admissible under
2 Rule 803(6). For the IMEs to be admitted under that rule, Plaintiffs must satisfy subparts
3 (A) through (D). Plaintiffs do not explain how these requirements will be met at trial, and
4 Defendant does not address them in any detail. If this were a jury trial, the Court likely
5 would need to resolve this issue before trial. Because this is a bench trial, it can be decided
6 during trial.

7 The Court notes, however, that the IMEs contain hearsay within hearsay, a fact not
8 addressed in any detail by the parties. The first level of hearsay – the IMEs themselves –
9 may be satisfied by Rule 803(6), but Plaintiffs must provide a basis for admission of other
10 hearsay statements within the IMEs. *See* Fed. R. Evid. 805. These include Mr. Alsadi’s
11 statements to the doctors, as well as statements from a variety of other sources. *See, e.g.,*
12 Doc. 149-3 at 3 (report by Bethanie Spangenberg, comments from Dr. Garcia, results of
13 pulmonary function study at Concerta, quotes from a radiologist who evaluated a CT scan);
14 *id.* at 5 (material safety data sheet for hydrogen sulfide, quote from bronchoscopy report);
15 Doc. 149-4 at 3 (quotes from Dr. Garcia’s notes). The parties should be prepared to address
16 these issues if the IMEs are introduced at trial.
17

18 **4. Rule 807.**


19 As amended just over one year ago, Rule 807 permits the admission of an out-of-court
20 statement that is not admissible under Rules 803 or 804 if the statement is supported by
21 sufficient guarantees of trustworthiness – after considering the totality of circumstances
22 under which it was made and evidence, if any, corroborating the statement – and it is more
23 probative on the point for which it is offered than any other evidence that the proponent can
24 obtain through reasonable efforts. Fed. R. Evid. 807(a)(1), (2). The Court cannot conclude
25 that the IMEs are admissible under this rule. Plaintiffs assert in a single conclusory
26 paragraph that Rule 807 is satisfied, and Defendant’s response is limited to one sentence in
27 a footnote. Furthermore, with the opinions of the doctors excluded as discussed above, the
28

1 probative value of the IMEs likely is limited to Mr. Alsadi's statements about his own history
2 and condition. The Court cannot conclude that the IMEs are more probative on these matters
3 than any other evidence Plaintiffs can present, including Mr. Alsadi's own testimony. If
4 Plaintiffs seek to admit the IMEs under Rule 807 at trial, they should be prepared to address
5 this point.

6 **C. Schwartzberg Deposition.**

7 Plaintiffs seek to admit portions of Dr. Schwartzberg's deposition and Defendant
8 seeks to exclude them, but no party describes what the depositions excerpts say. Instead,
9 Defendant argues that the deposition may not be used under any of the grounds set forth in
10 Federal Rule of Civil Procedure 32(a). Plaintiffs respond that Dr. Schwartzberg is
11 unavailable and that his deposition may therefore be used under Rule 32(a)(4)(D). Doc. 308
12 at 2 n.2. But in its reply, Defendant states that it is willing to help secure Dr. Schwartzberg's
13 participation in this remote trial or in serving a trial subpoena. Doc. 319 at 6. It therefore
14 appears that Dr. Schwartzberg is not unavailable for purposes of Rule 32(a)(4)(D). Plaintiffs
15 can work with Defendant to secure Dr. Schwartzberg's participation to the extent he can give
16 relevant testimony without expressing the opinions which have been excluded.
17

18 Dated this 5th day of January, 2021.

19
20 

21 David G. Campbell
22 Senior United States District Judge
23
24
25
26
27
28